OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients

被引：20

作者：

Zach, Otto ^{[1
]}

Krieger, Otto ^{[1
]}

Foedermayr, Mathilde ^{[1
]}

Zellhofer, Barbara ^{[1
]}

Lutz, Dieter ^{[1
]}

机构：

[1] Elisabeth Hosp, Dept Internal Med 1, A-4010 Linz, Austria

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 11期

关键词：

D O I：

10.1080/10428190802322893

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：2222 / 2223

页数：2

共 4 条

[1] Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program [J].

Gabert, J ;

Beillard, E ;

van der Velden, VHJ ;

Bi, W ;

Grimwade, D ;

Pallisgaard, N ;

Barbany, G ;

Cazzaniga, G ;

Cayuela, JM ;

Cavé, H ;

Pane, F ;

Aerts, JLE ;

De Micheli, D ;

Thirion, X ;

Pradel, V ;

González, M ;

Viehmann, S ;

Malec, M ;

Saglio, G ;

van Dongen, JJM .

LEUKEMIA, 2003, 17 (12) :2318-2357

[2] How I treat chronic myeloid leukemia in the imatinib era [J].

Goldman, John M. .

BLOOD, 2007, 110 (08) :2828-2837

[3] Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 [J].

Shu, Y ;

Leabman, MK ;

Feng, B ;

Mangravite, LM ;

Huang, CC ;

Stryke, D ;

Kawamoto, M ;

Johns, SJ ;

DeYoung, J ;

Carlson, E ;

Ferrin, TE ;

Herskowitz, I ;

Giacomini, KM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (10) :5902-5907

[4] Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity [J].

White, Deborah L. ;

Saunders, Verity A. ;

Dang, Phuong ;

Engler, Jane ;

Venables, Amity ;

Zrim, Stephanie ;

Zannettino, Andrew ;

Lynch, Kevin ;

Manley, Paul W. ;

Hughes, Timothy .

BLOOD, 2007, 110 (12) :4064-4072

← 1 →